This site is intended for US healthcare professionals only. Visit Patient Site

TAKE A LOOK AT OUR RESOURCE
LIBRARY

Downloadable Resources

Filter by:

Our resource library covers a variety of topics including access, prior authorizations, and patient education

GEMTESA Get Set Tracker.

Let's Go Tracker

Patients can explore lifestyle tips to help manage OAB, worksheets to identify personal and treatment goals, and track progress with GEMTESA.

Download PDFEmail PDF

GEMTESA Patient Brochure.

GEMTESA Patient Brochure

Patients can learn about OAB, prevalence, lifestyle tips, and how GEMTESA may help reduce the symptoms of OAB.

Download PDFEmail PDF

GEMTESA Prior Authorization Checklist.

GEMTESA Prior Authorization Checklist

Prepare for prior authorizations with this checklist and find out more about access resources from Patient Connect Support.

Download PDFEmail PDF

Low-income Subsidy Information.

Low-income Subsidy Information

Get the facts on the Medicare Extra Help Program for people with limited income/resources.

Download PDFEmail PDF

Pharmacy-initiated Prior Authorization Requests Information.

Pharmacy-initiated Prior Authorization Requests Information

Find additional details about completing a pharmacy-initiated prior authorization request.

Download PDFEmail PDF

Prior Authorizations and Medical Exceptions Information.

Prior Authorizations and Medical Exceptions Information

See insights and support when additional steps are needed to obtain GEMTESA.

Download PDFEmail PDF

TRICARE® Formulary Card.

TRICARE® Formulary Card

Explore the position of GEMTESA on the TRICARE Uniform formulary and learn about the requirements for beneficiaries.

Download PDFEmail PDF

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

GEMTESA is contraindicated in patients with known hypersensitivity to vibegron or any components of GEMTESA. Hypersensitivity reactions, such as angioedema, have occurred.

WARNINGS AND PRECAUTIONS

Urinary Retention

Urinary retention has been reported in patients taking GEMTESA. The risk of urinary retention may be increased in patients with bladder outlet obstruction and also in patients taking muscarinic antagonist medications for the treatment of OAB. Monitor patients for signs and symptoms of urinary retention, particularly in patients with bladder outlet obstruction and patients taking muscarinic antagonist medications for the treatment of OAB. Discontinue GEMTESA in patients who develop urinary retention.

Angioedema

Angioedema of the face and/or larynx has been reported with GEMTESA. Angioedema has been reported to occur hours after the first dose or after multiple doses. Angioedema, associated with upper airway swelling, may be life-threatening. If involvement of the tongue, hypopharynx, or larynx occurs, immediately discontinue GEMTESA and provide appropriate therapy and/or measures necessary to ensure a patent airway.

ADVERSE REACTIONS

Most common adverse reactions (≥2%) reported with GEMTESA were headache, urinary tract infection, nasopharyngitis, diarrhea, nausea, and upper respiratory tract infection.

INDICATIONS AND USAGE

GEMTESA^® is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

GEMTESA is contraindicated in patients with known hypersensitivity to vibegron or any components of GEMTESA. Hypersensitivity reactions, such as angioedema, have occurred.

WARNINGS AND PRECAUTIONS

Urinary Retention

Urinary retention has been reported in patients taking GEMTESA. The risk of urinary retention may be increased in patients with bladder outlet obstruction and also in patients taking muscarinic antagonist medications for the treatment of OAB. Monitor patients for signs and symptoms of urinary retention, particularly in patients with bladder outlet obstruction and patients taking muscarinic antagonist medications for the treatment of OAB. Discontinue GEMTESA in patients who develop urinary retention.

Angioedema

Angioedema of the face and/or larynx has been reported with GEMTESA. Angioedema has been reported to occur hours after the first dose or after multiple doses. Angioedema, associated with upper airway swelling, may be life-threatening. If involvement of the tongue, hypopharynx, or larynx occurs, immediately discontinue GEMTESA and provide appropriate therapy and/or measures necessary to ensure a patent airway.

ADVERSE REACTIONS

Most common adverse reactions (≥2%) reported with GEMTESA were headache, urinary tract infection, nasopharyngitis, diarrhea, nausea, and upper respiratory tract infection.

Please see full Prescribing Information.